



**September 18, 2023** 

### **Addressing Respiratory Challenges in ALS**

**Guest Speaker:** 

Kristen McHenry, EdD, RRT-ACCS Boise State University East Tennessee State University Gary E Shealy Memorial ALS Clinic

ALS Association National Office-Care Services Ph: 800-782-4747 Cynthia.Knoche@als.org



Living with ALS Webinar Series: September 18, 2023

# Addressing Respiratory Challenges in ALS

**Presenter: Kristen McHenry EdD, RRT-ACCS** 

### **Disclosures**

- I do NOT have any relevant financial relationships with any commercial interests.
- Teach in RT degree advancement (DA) programming (BS & MS)
- Board member, Commission on Accreditation for Respiratory Care (CoARC)
- Voluntary staff therapist at a multidisciplinary ALS clinic since 2016



# **Objectives**

# As a result of attending today's webinar, the learner will be able to:

- Identify how ALS impacts the respiratory system
- Discuss options currently available to help aid in the respiratory management of the pALS
- Approach the multidisciplinary team with questions and preferences regarding their respiratory care



### **How ALS presents itself**



- Affects motor nerve cells in brain and spinal cord which results in loss of muscle control
  - Speaking
  - Swallowing
  - Walking
  - Grasping
  - Breathing
- Limb Onset
  - Trouble grasping with hands
  - Tripping, dropping things
- Bulbar Onset
  - Tongue fasciculations
  - Dysphagia, sialorrhea

# **Respiratory Involvement**

- Less than 3% of cases present with respiratory symptom onset initially
- Respiratory involvement eventually occurs in all patients with ALS
- Pulmonary complications are a heightened concern in the disease process
- Weak muscles of the diaphragm and muscles of respiration result in
  - Difficulty inhaling sufficient air with each breath
  - Difficulty clearing the airway with a strong cough
- Respiratory symptoms include poor sleep quality, low oxygen levels (especially during sleep), difficulty breathing while lying flat, excessive daytime sleepiness, headaches, rapid/shallow breathing, and shortness of breath with or without exertion

## **Goals of Care when Respiratory System is Affected**

- 1. Prevent chest/respiratory infections (through appropriate vaccinations)
- 1. Decrease work of breathing (consider noninvasive ventilation)
- 1. Maintain a patent airway (manually assisted cough, mechanical assisted cough, secretion management, suction machine, or invasive ventilation)
- 1. Treat any infections or respiratory insufficiency/failure as it occurs
- 1. Enhance survivability and maximize quality of life as able

# What guides our respiratory recommendations?

- 1. Practice Parameter update: The care of the patient with amyotrophic lateral sclerosis: Drug, nutritional, and **respiratory therapies** (an evidencebased review). <u>2009</u>
- 1. Respiratory Management of Patients With Neuromuscular Weakness: An American College of Chest Physicians Clinical Practice Guideline and Expert Panel Report. 2023
- Discussion with our pALS concerning their preferences for care\*



# **AAN: Respiratory Management Algorithm**



### Key Components of Algorithm:

- PFT/spirometry every 3-6 months
  - Multidisciplinary clinic preferred
- Airway clearance strategies
  - Manual v. mechanical
- Secretion/sputum management
  - Suction, medications
- Measure respiratory muscle strength
  - MIP, SNP, MEP
- Ventilation
  - NIV or invasive, overnight oximetry

# **Respiratory Evaluation**

### Need for ventilation assistance:

- Orthopnea (difficulty lying flat)
- □ Sniffing nasal pressure (< 40 cm H2O)
- Maximal inspiratory pressure ( < -60 cmH2O)</li>
- Abnormal oxygen saturation during sleep
- Forced (or slow) vital capacity < 50% of predicted values (sitting or supine)</p>
- PaCO2 > 45 mmHg

### Need for cough assistance:

- Peak expiratory cough flow < 270 L/m</p>
- Maximum expiratory pressure < 40 cmH2O



# **Respiratory Monitoring**

### Forced vital capacity (FVC)

- Maximum amount of air that that can be exhaled as quickly and forcefully as possible after maximum inspiration
- Based on age, gender, height, ethnicity, and weight



### Maximum inspiratory pressure (MIP)

- Maximum amount of negative pressure generated during inspiration through an occluded system
- Decline in MIP may occur 4-6 months befc



# **Respiratory Monitoring**

### Sniff nasal pressure

- Noninvasive means of measuring inspiratory muscle strength
- May be easier for some patients when compared to MIP
- Correlates to decline in FVC and hypercapnia

### Maximum expiratory pressure

• Highest positive pressure that can be generated during a forced expiration against an occluded airway



### **Cough for Airway Clearance & Protection**



B

https://clinicalgate.com/airway-clearance-therapy/

# Manual Cough Assistance Options



### Abdominal thrust maneuver

### Glossopharyngeal "frog" breathing



#### **Respiratory Challenges**

https://www.atsjournals.org/doi/pdf/10.1164/rccm.201012-2031IM



# **Mechanical Cough Assistance Options**



- Mechanical insufflation-exsufflation (MIE) or "Cough Assist"
- Inspiratory and expiratory pressures are set based on patient tolerance and clearability of proximal secretions
- Generally 20-40 cmH2O
- Helpful in the presence of pulmonary infections
- May reduce morbidity and hospitalization
- May be less effective in those with bulbar involvement

# **Managing Secretions**

### Dysphagia (difficulty swallowing)

- Restricted tongue movement/mouth opening, bulbar muscle atrophy, and laryngeal dysfunction are all characteristics of advanced dysphagia in ALS
- Altered respiratory-swallow phase pattern in subjects with ALS with higher rates of non-ideal exhalation surrounding the swallowing movement

### Sialorrhea (excessive oral secretions)

- Average salivary production is roughly 0.5-1.5 L/day and any loss of clearability can fall within a spectrum of mild inconvenience to respiratory distress depending on the degree of overwhelm
- Oral Secretion Scale (OSS) can be used at the bedside to measure secretions relative to the individual's ability to swallow

### **Oral Secretion Scale**

OSS Score	Oral Secretion Characteristics	Saliva Swallow Ability
4, Normal	No excessive secretions	Automatic, normal
3, Mild	Infrequent, small accumulation of secretions in the mouth; infrequent wet lips or drooling; infrequent lip blotting	Automatic, decreased
2, Moderate	Occasional drooling, lip blotting; occasional pooling of secretions in the throat; oropharyngeal suctioning 0-2/h	Conscious, required
1, Severe	Frequent drooling, lip blotting; frequent pooling of secretions in the throat; oropharyngeal suctioning 3-4/h	Conscious, difficult
0, Most severe	Constant drooling, lip blotting; constant pooling of secretions in the throat; oropharyngeal suctioning >4/h	Conscious, impossible

The observer chooses a single score whose criteria most closely match the patient's condition, according to the worst performance; if multiple criteria in multiple score categories are observed, then the observer selects the score with the most criteria that match the patient's worst performance; if the observer is uncertain whether the patient has an OSS score of 3 or 2 or an OSS score of 1 or 0, the observer chooses the worst score as the default.

# **Managing Secretions**

Therapy	Suggestions	Remarks
Anticholinergic medications	<ul> <li>An initial trial of an inexpensive oral anticholinergic is suggested.</li> <li>Continue to use if the benefits are greater than the side effects.</li> <li>More expensive and potentially longer-acting anticholinergic patch medication also can be considered.</li> </ul>	<ul> <li>Relatively inexpensive and readily available.</li> <li>Individual patient benefits and adverse events can be assessed easily.</li> </ul>
Botulinum toxin therapy to salivary glands	<ul> <li>Limited data, doses are not defined.</li> <li>See individual studies for doses in e-Table 8b.</li> </ul>	<ul> <li>Inexpensive, lasting beneficial effects on salivary function.</li> <li>May need to be repeated. Associated with viscous saliva and mild to moderate pain.</li> </ul>
Salivary gland RT	<ul> <li>Limited data, doses not defined.</li> <li>See individual studies for doses e-Table 8c.</li> </ul>	<ul> <li>Long-lasting relief; however, associated with irreversible dryness.</li> <li>Suggest reserving RT to experienced centers.</li> </ul>

#### TABLE 4 ] Recommended Therapies for Sialorrhea

RT = radiation therapy.

# **Managing Secretions**







Anticholinergics: Glycopyrrolate, hyoscyamine, scopolamine patch, atropine drops

# Radiation therapy or botulinum toxin injection

**Surgery**: Total laryngectomy



# **Initiation of Noninvasive Ventilation**



- Early use has shown to increase mean survival rate (before FVC < 50%)
- Goal of at least four hours per day
- Use of ventilation support may not stop the progression of ALS, but can
  - Increase energy
  - Improve dyspnea
  - Greater sleep quality
  - Enhanced concentration
  - Decrease fatigue/depression
  - Lengthen survival
  - Slow rate of FVC decline
  - Enhance QoL

### **Respiratory Challenges**

https://journal.chestnet.org/article/S0012-3692(23)00353-7/fulltext

# **NIV Interface Options**







Nasal Mask

### Full Face Mask Hybrid



### **NIV Interface Options**





Mouthpiece Ventilation, Sometimes called "sip and puff"



# **NIV Compliance/Tolerance**

- Bulbar involvement = decreased tolerance to NIV
- Cognition level of patient and characteristics of caregiver
- Participation in multidisciplinary clinic with respiratory/pulmonary involvement has been shown to increase use of/access to NIV



# **Additional Treatment Options**

If NIV is declined or not tolerated, discuss other treatment options:

- Tracheostomy with invasive ventilation (TIV)
- Discuss withdrawal conditions if TIV is accepted
- Personal, financial, cultural factors leading to the decision
- Ventilation settings should be evaluated frequently and adjusted as needed



# **Invasive Ventilation**

B





# **Hospice & Palliative Care**



#### **Respiratory Challenges**

B

-https://iamals.org/get-help/palliative-and-hospice-care-for .als/#:~:text=Palliative%20care%20is%20available%20to,are%20no%20longer%20seeking%20treatment

# **Multidisciplinary Approach**



\*Also work closely with Neurologists/Pulmonologists, ALS Association Reps, Equipment Specialists

# **ALS Functional Rating Scale**

### Dyspnea

### Respiratory Insufficiency

None	+4
Occurs when walking	+3
Occurs with one or more of the following: eating, bathing, dressing	+2
Occurs at rest, difficulty breathing when either sitting or lying	+1
Significant difficulty, considering using mechanical respiratory support	0

None	+4
Some difficulty sleeping at night due to shortness of breath; does not routinely us	e
>2 pillows Needs extra pillows in order to sleep (>2)	+3
Can only sleep sitting up	+2
Unable to sleep	0

### Orthopnea

None	+4
Intermittent use of BiPAP	+3
Continuous use of BiPAP during the night	+2
Continuous use of BiPAP during the night and day	+1
Invasive mechanical ventilation by intubation or tracheostomy	0

### **Respiratory Challenges**

https://www.mdcalc.com/calc/10166/revised-amyotrophic-lateral-sclerosis-functional-rating-scale-alsfrs-

# **Questions to Ask your RT**

- Know your numbers! Do the results of pulmonary function testing indication respiratory involvement?
- What airway clearance strategies are ideal for my current status?
- What secretion management options are available for me?
- What type of ventilation support is right for me?





ALS Association. (2023). Understanding ALS. https://www.als.org/understanding-als/what-is-als

Cazzolli, PA et al. (2020). The Oral Secretion Scale and Prognostic Factors for Survival in Subjects With Amyotrophic Lateral Sclerosis. *Respiratory Care*, 65(8), 1063-1076. <u>https://doi.org/10.4187/respcare.07005</u>

I am ALS. (2023). *Palliative and hospice care for ALS*. <u>https://iamals.org/get-help/palliative-and-hospice-care-for-als/#:~:text=Palliative%20care%20is%20available%20to,are%20no%20longer%20seeking%20treatment</u>.

Khan, A et al. (2023). Respiratory Management of Patients With Neuromuscular Weakness: An American College of Chest Physicians Clinical Practice Guideline and Expert Panel Report. *CHEST,* 164(2), 394-413. <u>https://doi.org/10.1016/j.chest.2023.03.011</u>

MD Calc. (2023). *Revised Amyotrophic Lateral Sclerosis Functional Rating Scale* (ALSFRS-R). <u>https://www.mdcalc.com/calc/10166/revised-amyotrophic-lateral-sclerosis-functional-rating-scale-alsfrs-r</u>

Miller, RG et al. (2009). Practice Parameter update: The care of the patient with amyotrophic lateral sclerosis: Drug, nutritional, and respiratory therapies (an evidence-based review). *Neurology*, 73(15), 1218-1226. <u>https://doi.org/10.1212/WNL.0b013e3181bc0141</u>

### Gary E. Shealy Memorial ALS Clinic https://www.etsu.edu/crhs/als-clinic/ 423-439-4712

Thank you for your time and attention!

F